Mutations Clinical Trials

53 recruitingLast updated: July 25, 2026

There are 53 actively recruiting mutations clinical trials across 27 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include New York, New York, United States, Shanghai, Shanghai Municipality, China, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Mutations Trials at a Glance

53 actively recruiting trials for mutations are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 2 with 22 trials, with the heaviest enrollment activity in New York, Shanghai, and Houston. Lead sponsors running mutations studies include Jiangsu HengRui Medicine Co., Ltd., M.D. Anderson Cancer Center, and National Cancer Institute (NCI).

Browse mutations trials by phase

Treatments under study

About Mutations Clinical Trials

Looking for clinical trials for Mutations? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mutations trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mutations clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 53 trials

Recruiting
Phase 1

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Duke Street Bio Ltd180 enrolled18 locationsNCT06458712
Recruiting

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NeoplasmsLi-Fraumeni SyndromeTp53 Mutations
National Cancer Institute (NCI)5,000 enrolled2 locationsNCT01443468
Recruiting
Phase 2

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

NSCLC (Non-small Cell Lung Carcinoma)EGFR Uncommon MutationsStage III
Hunan Cancer Hospital15 enrolled1 locationNCT07314216
Recruiting
Phase 2

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Shanghai Junshi Bioscience Co., Ltd.35 enrolled2 locationsNCT07518160
Recruiting

Fibroblast Line Evaluation for COL5A eXpression and Thoracic Aortic Aneurysms: in Vitro Characterization of Cutaneous Fibroblasts in Adult Patients

Aneurysm AorticMutations Affecting the COL5A Gene
IRCCS Policlinico S. Donato20 enrolled1 locationNCT07282717
Recruiting
Phase 3

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled78 locationsNCT07185997
Recruiting
Phase 1

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Endometrial CancerHER2-low Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Cogent Biosciences, Inc.90 enrolled4 locationsNCT07383506
Recruiting
Phase 1Phase 2

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Regeneron Pharmaceuticals36 enrolled16 locationsNCT05788536
Recruiting

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Familial CancerMesotheliomaBRCA1-Associated Protein-1 (BAP1) Mutations+1 more
National Cancer Institute (NCI)300 enrolled1 locationNCT04431024
Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1Phase 2

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Metastatic Colorectal CancerKRAS G12C Mutations
M.D. Anderson Cancer Center31 enrolled2 locationsNCT06412198
Recruiting

Vascular Disease Discovery Protocol

Vascular DysfunctionGenetic PredispositionGenetic Mutations
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT03538639
Recruiting
Phase 1Phase 2

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Precision BioSciences, Inc.18 enrolled2 locationsNCT07429240
Recruiting
Phase 2

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Myelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid Leukemia+2 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT04493164
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd67 enrolled14 locationsNCT05886920
Recruiting

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

GliomasGlioma Glioblastoma MultiformeGliomas Harboring IDH1 and/or IDH2 Mutations+3 more
Xiangya Hospital of Central South University500 enrolled1 locationNCT07608003
Recruiting
Phase 2Phase 3

Spironolactone Improved Children With Gene Mutations Related to NCOR

ASDNCOR Gene MutationsSpironolactone
Qilu Hospital of Shandong University2 enrolled1 locationNCT06678685
Recruiting
Not Applicable

Early Diagnosis of High-grade Serous Epithelial Ovarian Cancer Through the Analysis of DNA Derived From Pap Test Smear.

Germline Mutations
Fondazione Policlinico Universitario Agostino Gemelli IRCCS260 enrolled1 locationNCT07556562
Recruiting
Phase 1

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Solid TumorsNSCLCEGFR Exon 20 Insertion Mutations+1 more
ORIC Pharmaceuticals76 enrolled4 locationsNCT06816992
Recruiting
Phase 2

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Targeted TherapyIDH1-Mutated MalignanciesMutations
M.D. Anderson Cancer Center68 enrolled1 locationNCT07032727